Skip to Content
Merck
CN
All Photos(2)

Documents

569396

Sigma-Aldrich

Staurosporine

from Streptomyces sp., ≥97% (HPLC), liquid, protein kinase inhibitor, Calbiochem

Sign Into View Organizational & Contract Pricing
All Photos(2)
Synonym(s):
InSolution Staurosporine, Streptomyces sp., PKA Inhibitor II, MLCK Inhibitor I
Empirical Formula (Hill Notation):
C28H26N4O3
CAS Number:
62996-74-1
Molecular Weight:
466.53
MDL number:
MFCD00077402
UNSPSC Code:
12352200
NACRES:
NA.77

product name

Staurosporine, Streptomyces sp., InSolution, ≥97%, 1 mM solution, protein kinase inhibitor

Quality Level

100

Assay

≥97% (HPLC)

form

liquid

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze
protect from light

shipped in

wet ice

storage temp.

−70°C

InChI

1S/C28H26N4O3/c1-28-26(34-3)17(29-2)12-20(35-28)31-18-10-6-4-8-14(18)22-23-16(13-30-27(23)33)21-15-9-5-7-11-19(15)32(28)25(21)24(22)31/h4-11,17,20,26,29H,12-13H2,1-3H3,(H,30,33)/t17-,20-,26-,28+/m1/s1

InChI key

HKSZLNNOFSGOKW-FYTWVXJKSA-N

General description

A potent, cell-permeable broad spectrum inhibitor of protein kinases. Inhibits CaM kinase (IC50 = 20 nM), myosin light chain kinase (IC50 = 1.3 nM), protein kinase A (IC50 = 7 nM), protein kinase C (IC50 = 0.7 nM), and protein kinase G (IC50 = 8.5 nM). Also inhibits platelet aggregation induced by collagen or ADP but has no effect on thrombin-induced platelet aggregation. Induces apoptosis in human malignant glioma cell lines. Arrests normal cells at the G1 checkpoint.

Biochem/physiol Actions

Cell permeable: yes
Primary Target
PKA
Product competes with ATP.
Reversible: yes
Target IC50: 7 nM, 20 nM, 1.3 nM, 700 pM, 8.5 nM, against protein kinase A , CaM kinase, myosin light chain kinase, protein kinase C, and protein kinase G, respectively

Packaging

Packaged under inert gas

Warning

Toxicity: Irritant (B)

Physical form

A 1 mM (100 µg/214 µl) solution of Staurosporine (Cat. No. 569397) in DMSO.

Reconstitution

Following initial thaw, aliquot, purge with inert gas, and freeze (-70°C).

Other Notes

Couldwell, W.T., et al. 1994. FEBS Lett.345, 43.
Nishimura, H. and Simpson, I.A. 1994. Biochem. J.302, 271.
Bruno, S., et al. 1992. Cancer Res.52, 470.
Kiss, Z. and Deli, E. 1992. Biochem. J.288, 853.
Vitale, M.L., et al. 1992. Neuroscience51, 463.
Hoffman, R. and Newland, E.S. 1991. Cancer Chemotherap. Pharmacol.28, 102.
Oka, S., et al. 1986. Agric. Biol. Chem.50, 2723.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

WGK

WGK 1

Flash Point(F)

(Dimethylsulfoxide)

Flash Point(C)

(Dimethylsulfoxide)

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Shuai Guo et al.
British journal of pharmacology, 179(21), 4974-4991 (2022-07-15)
Macrophage-rich atherosclerotic arteries are highly active in glycolysis. PFKFB3, a key glycolytic enzyme, has emerged as a potential therapeutic target in atherosclerosis. Small-molecule inhibitors of PFKFB3, such as 3PO and PFK158, have demonstrated efficacy in hampering atherogenesis in preclinical models.
Liaisan Arslanbaeva et al.
Redox biology, 51, 102272-102272 (2022-03-08)
Cutaneous melanoma is the deadliest type of skin cancer, although it accounts for a minority of all skin cancers. Oxidative stress is involved in all stages of melanomagenesis and cutaneous melanoma can sustain a much higher load of Reactive Oxygen
Erin R Spiller et al.
Frontiers in oncology, 11, 771173-771173 (2022-01-08)
Three-quarters of compounds that enter clinical trials fail to make it to market due to safety or efficacy concerns. This statistic strongly suggests a need for better screening methods that result in improved translatability of compounds during the preclinical testing
Marco Ponzetti et al.
Frontiers in oncology, 12, 983254-983254 (2022-12-23)
Osteosarcoma is the most common primary bone malignancy. The crosstalk between osteosarcoma and the surrounding tumour microenvironment (TME) drives key events that lead to metastasization, one of the main obstacles for definitive cure of most malignancies. Extracellular vesicles (EVs), lipid

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service